Arvinas Inc Total Assets
Arvinas Inc total assets. Based on the latest financial reports, Arvinas Inc (ARVN) holds total assets worth $675.10 Million USD as of June 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see how much is Arvinas Inc worth for the company's overall valuation and market capitalisation.
Total Assets of Arvinas Inc (2016–2025)
Total assets of Arvinas Inc from 2016 to 2025. This chart illustrates how Arvinas Inc's total assets have evolved over time, based on quarterly financial data. See ARVN live share price for real-time trading data and today's change.
Arvinas Inc - Asset Composition Analysis
Arvinas Inc Total Assets Breakdown (December 2025)
Arvinas Inc total assets breakdown as of December 2025. Arvinas Inc's total assets of $675.10 Million consist of 97.6% current assets and 2.4% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 19.9% |
| Accounts Receivable | $6.40 Million | 0.9% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2025)
This chart illustrates how Arvinas Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore ARVN net working capital ratio to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Arvinas Inc's current assets represent 97.6% of total assets in 2025, a decrease from 98.3% in 2016.
- Cash Position: Cash and equivalents constituted 19.9% of total assets in 2025, up from 13.4% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 0.9% of total assets.
Arvinas Inc Competitors by Total Assets
Key competitors of Arvinas Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Arvinas Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 7.91 | 5.64 | 8.64 |
| Quick Ratio | 7.91 | 5.64 | 8.61 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $569.70 Million | $731.70 Million | $1.39 Billion |
Arvinas Inc - Advanced Valuation Insights
This section examines the relationship between Arvinas Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.91 |
| Latest Market Cap to Assets Ratio | 0.67 |
| Asset Growth Rate (YoY) | -34.2% |
| Total Assets | $717.90 Million |
| Market Capitalization | $484.55 Million USD |
Valuation Analysis
Below Book Valuation: The market values Arvinas Inc's assets below their book value (0.67x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Arvinas Inc's assets decreased by 34.2% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Arvinas Inc (2016–2025)
The table below shows the annual total assets of Arvinas Inc from 2016 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $717.90 Million | -34.22% |
| 2024-12-31 | $1.09 Billion | -16.34% |
| 2023-12-31 | $1.30 Billion | +2.82% |
| 2022-12-31 | $1.27 Billion | -19.78% |
| 2021-12-31 | $1.58 Billion | +120.46% |
| 2020-12-31 | $717.40 Million | +137.83% |
| 2019-12-31 | $301.64 Million | +51.36% |
| 2018-12-31 | $199.28 Million | +198.11% |
| 2017-12-31 | $66.85 Million | +76.21% |
| 2016-12-31 | $37.94 Million | -- |
About Arvinas Inc
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. It is also developing… Read more